Targeting VEGF/VEGFR to Modulate Antitumor Immunity

In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 9; p. 978
Main Authors: Yang, Ju, Yan, Jing, Liu, Baorui
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 03.05.2018
Subjects:
angiogenesis
Angiogenesis Inhibitors - pharmacology
Animals
Cell Differentiation - immunology
Dendritic Cells - immunology
Humans
immune
Immunologic Factors - pharmacology
Immunology
Mice
Myeloid-Derived Suppressor Cells - immunology
Neoplasms - immunology
Neovascularization, Pathologic
Receptors, Vascular Endothelial Growth Factor - immunology
T cells
T-Lymphocytes, Regulatory - immunology
tumor
vascular endothelial growth factor
Vascular Endothelial Growth Factors - immunology
immune
T cells
angiogenesis
tumor
vascular endothelial growth factor
ISSN:1664-3224, 1664-3224
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the differentiation and activation of dendritic cells (DCs). Recent studies have investigated the role of antiangiogenic agents in antitumor immunity, especially in recent 3 years. Therefore, it is necessary to update the role of targeting VEGF/VEGFR in antitumor immunity. In this review, we focus on the latest clinical and preclinical findings on the modulatory role of antiangiogenic agents targeting VEGF/VEGFR in immune cells, including effector T cells, Tregs, MDSCs, DCs, tumor-associated macrophages, and mast cells. Our review will be potentially helpful for the development of combinations of angiogenesis inhibitors with immunological modulators.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Giovanna Schiavoni, Istituto Superiore di Sanità, Italy
Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Reviewed by: Anca Maria Cimpean, Victor Babes University of Medicine and Pharmacy Timisoara, Romania; Barbara Ghinassi, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.00978